Zepbound®

The easiest way to find out is to start. Our US-licensed provider partners review a short online intake — usually just a few minutes — and determine what's right for you on an individual basis, based on your health history and goals. There's no cost to find out and no obligation.

Yes. Shipping is always free, and every order arrives in plain, unmarked packaging from a US-licensed pharmacy — no one needs to know what's inside. Most orders arrive within about a week of approval.

Yes. Pallas is a cash-pay medical service, and we provide an itemized receipt for your visit and prescription that you can submit to your FSA or HSA. Most plans treat prescription medications and telehealth visits as eligible expenses — your plan administrator can confirm what applies to you.

We'll make it right. Pallas includes unlimited customer support — if anything's off with your shipment, or you simply have a question about your treatment, our support team and your care team are a message away, as often as you need, at no extra cost.

Pallas is cash-pay and doesn't bill insurance directly — that keeps your pricing simple and predictable. But because you receive the genuine, FDA-approved product with an itemized receipt, some patients choose to submit a claim to their insurer afterward for possible out-of-network reimbursement. Whether it's reimbursed is up to your individual plan.

Zepbound^® is the brand name for FDA-approved tirzepatide, manufactured by Eli Lilly for chronic weight management. Tirzepatide activates both the GIP and GLP-1 receptors, and is delivered as a once-weekly subcutaneous injection.

Zepbound^® is $1,069/month on Pallas — billed flat, cash-pay, with no insurance routing. The price covers a 28-day supply shipped from a US-licensed pharmacy. For comparison, Zepbound^®'s pharmacy list price without insurance is around $1,300/month, and Eli Lilly offers lower-dose self-pay vials through LillyDirect.

In the SURMOUNT-1 pivotal trial, participants on the 15 mg dose of tirzepatide lost an average of about 20.9% of body weight at 72 weeks alongside lifestyle intervention (New England Journal of Medicine, 2022). Individual results vary, and this outcome reflects the FDA-approved product under the conditions studied.

The most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal discomfort — usually most noticeable during dose increases and easing over time. Rare but serious risks include pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumors based on animal studies. People with a personal or family history of medullary thyroid carcinoma or MEN 2 should not use it. Review the full prescribing information and disclose your medical history to your clinician.

Tirzepatide is the active ingredient; Zepbound^® is the FDA-approved brand of tirzepatide for weight management (Mounjaro^® is the same molecule approved for type 2 diabetes). So FDA-approved Zepbound^® is tirzepatide. Compounded tirzepatide, however, is not the same as Zepbound^® — it is not FDA-approved, not a generic, and has not been evaluated by the FDA.

Zepbound^® contains tirzepatide (a dual GIP/GLP-1 agonist made by Eli Lilly), while Wegovy^® contains semaglutide (a GLP-1 agonist made by Novo Nordisk). Both are FDA-approved for chronic weight management. They differ in molecule, manufacturer, and clinical trial results — your clinician can help determine which is more appropriate for you.

Yes — no contracts and no lock-in. You can pause or cancel your plan anytime, right from your patient portal.